{
    "organizations": [],
    "uuid": "e5c8d8424fa529acb48a79d2e0f24436206dbd39",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-caladrius-biosciences-announces-co/brief-caladrius-biosciences-announces-completion-of-enrollment-of-phase-2-t-rex-clinical-trial-of-clbs03-for-type-1-diabetes-idUSASB0C1EH",
    "ord_in_thread": 0,
    "title": "BRIEF-Caladrius Biosciences Announces Completion Of Enrollment Of Phase 2 T-Rex Clinical Trial Of CLBS03 For Type 1 Diabetes",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 18 (Reuters) - Caladrius Biosciences Inc:\n* CALADRIUS BIOSCIENCES ANNOUNCES COMPLETION OF ENROLLMENT OF PHASE 2 T-REX CLINICAL TRIAL OF CLBS03 FOR TYPE 1 DIABETES\n* CALADRIUS BIOSCIENCES INC - TOPLINE DATA FROM PRIMARY ENDPOINT OF COMPLETED STUDY ON CLBS03 EXPECTED IN EARLY 2019 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-18T21:06:00.000+02:00",
    "crawled": "2018-01-19T12:18:41.012+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "caladrius",
        "bioscience",
        "inc",
        "caladrius",
        "bioscience",
        "announces",
        "completion",
        "enrollment",
        "phase",
        "clinical",
        "trial",
        "clbs03",
        "type",
        "diabetes",
        "caladrius",
        "bioscience",
        "inc",
        "topline",
        "data",
        "primary",
        "endpoint",
        "completed",
        "study",
        "clbs03",
        "expected",
        "early",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}